We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate the Safety and Efficacy of ZS801 in Adult Hemophilia B Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05641610
Recruitment Status : Not yet recruiting
First Posted : December 7, 2022
Last Update Posted : December 7, 2022
Sponsor:
Information provided by (Responsible Party):
Institute of Hematology & Blood Diseases Hospital

Brief Summary:
A non-randomized, open-label, dose-escalation, phase I/II study to evaluate the safety, tolerability, kinetics and efficacy of a single intravenous infusion of ZS801 in hemophilia B subjects with endogenous FIX ≤2%.

Condition or disease Intervention/treatment Phase
Hemophilia B Genetic: ZS801 Phase 1 Phase 2

Detailed Description:

This study will seek to determine the safety, tolerability, kinetics and efficacy of a single IV infusion of ZS801.

Hemophilia B is a genetic bleeding disorder resulting in the lack of ability to produce blood-clotting factor IX (FIX). Individuals with hemophilia B suffer repeated bleeding events, which can cause chronic joint disease and sometimes leads to death due to the inability for blood to clot efficiently. The current treatment is intravenous infusion of FIX protein products, either prophylactically or in response to bleeding.

ZS801 is an adeno-associated viral (AAV) vector designed to drive expression of the human factor IX (hFIX) transgene and raise circulating levels of endogenous FIX.

Dose-escalation phase: 16 patients will be enrolled sequentially every 3 weeks or more between cohorts and administered with single infusion of ZS801. Dose escalation may occur based on the safety and FIX activity on steady state. The dose levels are as follows: 2.0×10^12vg/kg, 5.0×10^12vg/kg, 1.0×10^13vg/kg.

Dose-expansion phase: 5 patients will be enrolled and be administrated of ZS801.

Subjects will provide informed consent and then undergo screening assessments up to 6-8 weeks prior administration of ZS801. All subjects will undergo 52 weeks safety and efficacy observation.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 21 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Hemophilia B patients
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Non-randomized, Open-label, Dose-escalation, Phase I/II Study to Evaluate the Safety, Tolerability, Kinetics and Efficacy of a Single Intravenous Infusion of ZS801 in Hemophilia B Subjects With Endogenous FIX ≤2%.
Estimated Study Start Date : December 2022
Estimated Primary Completion Date : December 2024
Estimated Study Completion Date : December 2028

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: ZS801
Single intravenous (i.v.) infusion of ZS801 Intervention: Gene Therapy / Gene Transfer
Genetic: ZS801
A novel, bioengineered adeno-associated viral (AAV) vector carrying human factor IX variant. The dose levels are as follows: 2.0×10^12vg/kg, 5.0×10^12vg/kg, 1.0×10^13vg/kg.




Primary Outcome Measures :
  1. Incidence of adverse events [ Time Frame: Baseline up to Week 52 ]
    An adverse event (AE) is any medical occurrence, the event will not relate to the treatment.

  2. Number of participants with clinically significant change from baseline in vital signs [ Time Frame: Baseline up to Week 52 ]
    Vital signs will be obtained with participants in the seated position, after having sat calmly for at least 5 minutes. The clinical significance of vital signs will be determined at the investigator's discretion.

  3. Number of participants with clinically significant change from baseline in physical examination findings [ Time Frame: Time Frame: Baseline up to Week 52 ]
    Findings will be considered to be clinically significant based on the investigator's decision.

  4. Number of participants with clinical laboratory abnormalities [ Time Frame: Baseline up to Week 52 ]
    Findings were considered to be clinically significant based on the investigator's decision.

  5. Antibody against AAV capsid protein [ Time Frame: Baseline up to Week 52 ]
    Immune response against AAV capsid will be evaluated by measurement of the binding antibody and neutralizing antibody against AAV capsid protein in plasma samples.


Secondary Outcome Measures :
  1. Vector-derived FIX activity levels [ Time Frame: Baseline up to Week 52 ]
    The vector-derived endogenous FIX activity levels will be measured by One-Stage clot (OS) assay, and characterized by post-treatment population mean and its change from baseline during each visit.

  2. Vector-derived FIX antigen levels [ Time Frame: Baseline up to Week 52 ]
    The vector-derived endogenous FIX antigen levels will be characterized by post-treatment population mean, and its change from baseline during each visit.

  3. Vector shedding of ZS801 [ Time Frame: Baseline up to Week 52 ]
    Blood, saliva, urine and semen will be collected to assess clearance of vector genomes.


Other Outcome Measures:
  1. Annualized bleeding rate changes from baseline [ Time Frame: Baseline up to Week 52 ]
    The number of bleeding episodes per participant will be recorded, and the annualized number of bleeding episodes was calculated.

  2. Annualized FIX consumption changes from baseline [ Time Frame: Baseline up to Week 52 ]
    The use of FIX replacement therapy will be recorded by dose (IU/kg) administered, and the annualized use of FIX replacement therapy will be calculated.

  3. Number of target joints [ Time Frame: Baseline up to Week 52 ]
    The target joint is a minimum of three bleeds into a single joint within a consecutive 3-month period.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male ≥18 years of age;
  2. Confirmed diagnosis of hemophilia B, and endogenous FIX ≤2%;
  3. Have had ≥100 prior exposure days (EDs) to any recombinant and/or plasma-derived FIX protein products;
  4. The subject had at least 3 or more bleeding events and/or chronic hemophilia arthritis in one or more joints in the previous 1 year requiring treatment with FIX;
  5. Agree to use reliable barrier contraception and prohibition of sperm donation until 52 weeks after the administration of ZS801.
  6. Subjects voluntarily participate and are fully informed, fully understand the research and can comply with the requirements of the research protocol, are willing to complete the research as planned, and voluntarily cooperate with the provision of biological samples for testing.

Exclusion Criteria:

  1. Hypersensitivity to any component of the study drug (including immunosuppressants) or a condition that can not use;
  2. Inability to tolerate immunosuppressants or steroid drugs;
  3. Have FIX inhibitor as assessed by laboratory, or documented history of FIX inhibitor;
  4. Who have a history or are currently suffering from any of the following serious clinical diseases:

    1. History of malignancy or current presence of any malignancy;
    2. Have active autoimmune disease;
    3. Severe heart disease, including angina pectoris, myocardial infarction, heart failure, clinically significant congenital heart disease, heart valve disease, arrhythmia and atrioventricular block, etc.;
    4. Have underlying liver disease or history of liver disease (such as portal hypertension, ascites, splenomegaly, esophageal varices, hepatic encephalopathy or hepatic fibrosis);
    5. Have active hepatitis B infection (HBsAg positive) or active hepatitis C infection (HCVAb positive), or are currently receiving hepatitis B or hepatitis C antiviral therapy;
    6. Diabetes mellitus that is poorly controlled after drug treatment;
    7. Uncontrolled hypertension or hypotension;
  5. laboratory values:

    1. Hemoglobin<110g/L;
    2. Platelets<100×10^9/L;
    3. AST, ALT, alkaline phosphatase>2×ULN;
    4. Total bilirubin>1.5×ULN;
    5. Creatinine>ULN;
    6. Albumin<LLN;
    7. HIV antibody positive or Treponema pallidum antibody positive.
  6. Have AAV5 capsid neutralizing antibody titers >1:5;
  7. Those who have received clinical trials of gene therapy before screening, or have used FIX clinical trial drugs within 1 month, or participated in other drug/device clinical trials within 3 months, or plan to participate in other clinical trials during this study;
  8. Those who have planned surgery within 52 weeks after the infusion;
  9. Those who lost more than 400 mL of blood within 3 months before screening;
  10. Those with epilepsy, history of mental illness (such as schizophrenia, depression, mania or anxiety) or obvious mental disorder, incapacitated or incapacitated by other reasons;
  11. Patients with a history of drug abuse or alcoholism;
  12. Investigators believe that subjects have poor compliance or are expected to be less likely to complete follow-up;
  13. There are clinically significant diseases or other reasons that the researcher and/or collaborators consider unsuitable to participate in this researcher.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05641610


Contacts
Layout table for location contacts
Contact: Zhang Lei, MD +86 022-23909240 zhanglei1@ihcams.ac.cn

Locations
Layout table for location information
China, Tianjin
Institute of Hematology & Blood Diseases Hospital
Tianjin, Tianjin, China, 300020
Sponsors and Collaborators
Institute of Hematology & Blood Diseases Hospital
Investigators
Layout table for investigator information
Principal Investigator: Lei Zhang, MD Institute of Hematology & Blood Diseases Hospital
Layout table for additonal information
Responsible Party: Institute of Hematology & Blood Diseases Hospital
ClinicalTrials.gov Identifier: NCT05641610    
Other Study ID Numbers: ZS801-P01
First Posted: December 7, 2022    Key Record Dates
Last Update Posted: December 7, 2022
Last Verified: November 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: IPD will be shared with other researchers when ZS801 is fully approved
Supporting Materials: Study Protocol
Time Frame: IPD will be shared with other researchers when ZS801 is fully approved
Access Criteria: IPD will be shared with other researchers when ZS801 is fully approved

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Institute of Hematology & Blood Diseases Hospital:
Hemophilia B
Gene therapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Hemophilia A
Hemophilia B
Blood Coagulation Disorders, Inherited
Blood Coagulation Disorders
Hematologic Diseases
Coagulation Protein Disorders
Hemorrhagic Disorders
Genetic Diseases, Inborn
Genetic Diseases, X-Linked